Table 3.
Site |
Moran test |
PW test |
Estimation
a
|
CI
b
(95%) |
Exp (β) |
---|---|---|---|---|---|
p-value | p-value | EDI coefficient | |||
Breast |
< 0.025 |
< 0.05 |
-0.016 |
[-0.032; 0.001] |
|
Colon-rectum |
< 0.025 |
< 0.05 |
-0.001 |
[-0.026; 0.026] |
|
Corpus uteri |
< 0.025 |
< 0.05 |
0.024 |
[-0.011; 0.059] |
|
Lung |
< 0.025 |
< 0.05 |
0.075 |
[0.037; 0.113] |
1.08 |
Ovary |
0.69 |
< 0.05 |
-0.031 |
[-0.069; 0.006] |
|
Melanoma |
0.49 |
< 0.05 |
-0.028 |
[-0.068; 0.012] |
|
Non-Hodgkin lymphoma |
0.79 |
< 0.05 |
-0.004 |
[-0.046; 0.038] |
|
Thyroid |
< 0.025 |
< 0.05 |
0.002 |
[-0.043; 0.047] |
|
Central nervous system |
< 0.025 |
< 0.05 |
0.024 |
[-0.044; 0.051] |
|
Cervix uteri |
< 0.025 |
< 0.05 |
0.094 |
[0.052; 0.136] |
1.10 |
Kidney |
< 0.025 |
< 0.05 |
0.021 |
[-0.026; 0.068] |
|
Stomach |
< 0.025 |
< 0.05 |
0.007 |
[-0.052; 0.067] |
|
Pancreas |
0.05 |
< 0.05 |
0.045 |
[-0.004; 0.091] |
|
Unknown primary site |
0.56 |
< 0.05 |
0.065 |
[0.015; 0.113] |
1.08 |
Bladder |
< 0.025 |
< 0.05 |
0.033 |
[-0.023; 0.086] |
|
Lips-mouth-pharynx |
< 0.025 |
< 0.05 |
0.103 |
[0.054; 0.150] |
1.11 |
Myeloma |
0.35 |
< 0.05 |
-0.038 |
[-0.096; 0.020] |
|
Lymphocytic leukemia |
< 0.025 |
< 0.05 |
0.041 |
[0.024; 0.104] |
|
Leukemia |
0.04 |
< 0.05 |
-0.036 |
[-0.107; 0.034] |
|
Gall-Bladder and |
0.93 |
< 0.05 |
-0.014 |
[-0.097; 0.068] |
|
Extrahepatic bilary tract |
|
|
|
|
|
Liver |
< 0.025 |
< 0.05 |
0.078 |
[-0.002; 0.154] |
|
Esophagus |
0.40 |
< 0.05 |
0.068 |
[-0.017; 0.151] |
|
Hodgkin’s lymphoma |
0.33 |
0.11 |
|
|
|
Small intestine |
0.88 |
0.14 |
|
|
|
Larynx |
< 0.025 |
0.06 |
0.110 |
[-0.005; 0.217] |
|
Mesothelioma | < 0.025 | 0.05 | 0.040 | [-0.144; 0.205] |
aPositive for an over-incidence in deprived areas, negative otherwise.
bSignificant CIs are in bold type.